Device Trial Radar · NCT07902739
Pulsed Field Ablation of Atrial Fibrillation: CENTAURI Versus FARAPULSE
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
325
Actual
Start
May 17, 2024
Primary completion
Oct 5, 2026
Study completion Oct 5, 2026
Sponsor
- Lead sponsor
- St. Anne's University Hospital Brno, Czech RepublicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to compare the efficacy of two commercially available pulsed field ablation (PFA) systems for catheter ablation of atrial fibrillation. Patients are randomized 1:1 to point-by-point PFA using the CENTAURI PEF system with 3D electroanatomical mapping, or to single-shot PFA using the FARAPULSE pentaspline catheter guided by fluoroscopy and intracardiac echocardiography. The primary endpoint is freedom from documented atrial arrhythmia recurrence between 3 and 12 months after ablation.
Conditions
- Atrial Fibrillation (AF)
- Paroxysmal AF
- Persistent AF
Interventions
CENTAURI PEF systemDevice
Point-by-point pulsed field ablation using the CENTAURI generator connected to a contact-force sensing focal ablation catheter (TactiCath SE, Abbott), guided by the EnSite Precision 3D electroanatomical mapping system (Abbott). Pulmonary vein isolation is performed in all patients; additional ablation of low-voltage areas is at the operator's discretion. Procedure performed under general anesthesia.
FARAPULSE systemDevice
Single-shot pulsed field ablation using the FARAPULSE system (Boston Scientific) with a multielectrode pentaspline ablation catheter, guided by fluoroscopy and intracardiac echocardiography without a 3D mapping system. Pulmonary vein isolation is performed in all patients; additional ablation of low-voltage or fractionated areas is at the operator's discretion. Procedure performed under general anesthesia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from atrial arrhythmia recurrenceTime frame: 3 to 12 months after ablation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Anne's University Hospital Brno
Brno, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.